Cellectis Financial Update: Second Quarter Results Awaited

Author: Ryan Hughes Updated: 07-28-2025 04:38 PM

Cellectis to Release Financial Results for Q2 2025

Cellectis, a pioneer in biotechnology, is gearing up to share its financial performance for the second quarter of 2025. The anticipated report will cover essential metrics for the period ending June 30, revealing the progress made by this clinical-stage company.

Details on Financial Reporting

The financial results are expected to be made public on August 4, 2025, following the conclusion of the U.S. market. Investors and analysts will be keenly looking forward to these insights to gauge the company's performance.

Investor Conference Call Details

The announcement of the financial results will be followed by an investor conference call on August 5, 2025, at 8:00 AM ET. This call will serve not only to present the financial metrics but also to provide an update on ongoing business activities.

Contact Information for Investors

For those interested in participating in the conference call, specific dial-in information has been provided:

Domestic Call: +1-800-343-5172

International Call: +1-203-518-9856

Conference ID: CLLSQ2

About Cellectis

Cellectis is at the forefront of biotechnology, utilizing its groundbreaking gene-editing technologies to develop therapies aimed at treating cancer. Their innovative CAR T immunotherapy approach focuses on providing ready-to-use gene-edited cells for patient treatment. This advanced platform positions Cellectis as a leader in the gene therapy value chain, ensuring comprehensive control over development and manufacturing.

Global Presence and Commitment

The company operates from its headquarters in Paris, France, and maintains additional offices in New York and Raleigh, North Carolina. This geographic spread enhances their operational efficiency and capacity for innovation in the field of biomedicine.

Future Prospects for Cellectis

Looking ahead, Cellectis remains dedicated to advancing its CAR T-cell therapies and exploring other therapeutic indications that could greatly benefit patients. The focus on allogeneic therapies amidst rising oncology demands marks a strategic advantage within the biopharmaceutical landscape.

Media and Investor Relations

For more information about Cellectis and its exciting developments, you can reach out to:

Media Contact: Pascalyne Wilson, Director of Communications
+33 (0)7 76 99 14 33
media@cellectis.com

Investor Relations: Arthur Stril, Chief Financial Officer & Chief Business Officer
investors@cellectis.com

Frequently Asked Questions

What financial report is Cellectis set to publish?

Cellectis is preparing to release its financial results for the second quarter of 2025.

When will the financial results be available?

The financial results will be announced on August 4, 2025.

What is the conference call option for investors?

Investors can join a conference call on August 5, 2025, at 8:00 AM ET to discuss the results.

What makes Cellectis unique in biotechnology?

Cellectis is known for its pioneering gene-editing technology and its innovative approach to CAR T immunotherapy, focused on providing off-the-shelf solutions.

How can investors contact Cellectis for further information?

Investors can reach out to Arthur Stril at investors@cellectis.com for any inquiries.

About The Author

Hello, my name is Ryan Hughes. I am a financial, economics, and stock market specialist committed to assisting people in negotiating the intricacies of the financial system. Having a great deal of experience and a thorough grasp of market dynamics and economic trends, my area of expertise is converting complex financial ideas into understandable, practical knowledge. By use of my articles and blog entries, I hope to give you the information and assurance you need to make wise financial choices.

I've had the honor of interacting with a wide range of readers as a writer for several financial blogs, from new investors to seasoned market participants. To enable you to reach your financial goals, I want to make finance, economics, and stock market trends understandable and approachable. I appreciate you traveling with me toward success and financial literacy.

Contact Ryan Hughes privately here. Or send an email with ATTN: Ryan Hughes as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.